Agilent Technologies Inc.. (3/30/17). "Press Release: Agilent Technologies Showcases Cancer Research Innovations at AACR 2017". Santa Clara, CA.

	Region	Washington, D.C.
	Country	United States (USA)
	Product	AACR Annual Meeting 2017 Washington DC
	Product 2	SureSelectXT HS system
	Person	Wadsworth-Hansen, Victoria (Agilent 201506 Director Global Business Public Relations)

Focus on Technological Advances in Genomics and Cellular Analysis

Agilent Technologies Inc. (NYSE: A) today announced it will showcase some of its most recent technological advances in the areas of cell analysis and genomics at the AACR Annual Meeting 2017, being held April 1 - 5, 2017 in Washington, D.C.

Agilent will preview its newest next-generation sequencing (NGS) library prep solution – SureSelectXT HS – providing the first complete target enrichment solution, from quality control to target enrichment to analysis and interpretation, that is optimized for low-input formalin-fixed, paraffin-embedded (FFPE) samples. Additionally, SureSelectXT HS incorporates molecular barcodes, which improves precision and produces higher complexity libraries on a wide range of tissue types.

“With SureSelectXT HS, researchers will now be able to sequence deeper and achieve greater sensitivity, increasing confidence in their results,” said Rebecca Brandes, global marketing director for Cancer Genetics at Agilent Technologies. “Molecular barcodes increase variant calling accuracy, reduce false positive calls and improve data quality overall.”

Also on show at AACR will be the new Agilent Seahorse XF Glycolytic Rate Assay. This innovative assay is as accurate as a lactate assay, but provides more by reporting real time changes in both central cellular metabolic pathways, enabling the identification of how and when metabolic switches such as the Warburg effect occur. This ability to delineate the different energy pathways used by various tumors will help research scientists develop novel approaches to inhibit cancer cell survival and growth.

“Cancer cells can be dependent on pathways fueled by specific substrates for survival or proliferation, offering an opportunity to identify and confirm metabolic liabilities as therapeutic targets,” said David Ferrick, Ph.D., senior director of the Cell Analysis Division at Agilent Technologies. “The Agilent Seahorse XF assay platform enables the study of metabolic pathways and fuels that cancer cells depend on to generate energy.”

AACR 2017 will feature seminars and workshops conducted by leading scientists from around the world, including some Agilent customers. Visit Agilent Technologies at booth # 2429 to learn more.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A), a global leader in life sciences, diagnostics and applied chemical markets, is the premier laboratory partner for a better world. Agilent works with customers in more than 100 countries, providing instruments, software, services and consumables for the entire laboratory workflow. The company generated revenues of $4.20 billion in fiscal 2016 and employs about 12,500 people worldwide. Information about Agilent is available at www.agilent.com.

# # #

Contact:

Victoria Wadsworth-Hansen
Agilent Technologies
+1 408-553-2005
+45 29336980
victoria.wadsworth-hansen@agilent.com

Record changed: 2017-04-28

Top News

Upcoming Events

Management Appointments

Financings & Acquisitions

Collaborations & Licensing

At Investor Conferences

Associations

Advertise

Agilent Technologies Inc.. (3/30/17). "Press Release: Agilent Technologies Showcases Cancer Research Innovations at AACR 2017". Santa Clara, CA.

More documents for Agilent (Group)